Search for a trial

A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension

To evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension (PAH).

High dose statins in post-coarctectomy patients.

To reduce atherosclerotic progression in post-coarctectomy patients.

A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT Syndrome type 3.

The primary objective of this study is to evaluate in subjects with LQT3:- The effect of oral eleclazine on mean daytime QTcF interval (in msec) after 24 weeks of treatment with eleclazine (based on standard 12-lead electrocardiogram [ECG] data)The…

A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-8)

The primary objectives are to evaluate:-The effect of inclisiran treatment on the proportion of subjects achieving prespecified low densitylipoprotein cholesterol (LDL-C) targets at end of study (EOS)-The safety and tolerability profile of long term…

An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the adolescent ORION-16 or ORION-13 studies (VICTORION-PEDS-OLE)

This study has been transitioned to CTIS with ID 2023-507278-41-00 check the CTIS register for the current data. The primary objective of the study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH

A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults
with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM
(MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

This study has been transitioned to CTIS with ID 2022-502858-14-00 check the CTIS register for the current data. primary objective:To assess the long-term safety and tolerability of mavacamten in participants with hypertrophic cardiomyopathy (HCM)…